The poor prognosis of ovarian cancer, characterized by late diagnosis, high treatment resistance rates, and significant mortality, underscores the urgent need for improved prognostic and therapeutic strategies. In cancer patients, venous thromboembolism (VTE) is the second leading cause of death, with an even more pronounced impact in ovarian cancer due to the tumour’s biological characteristics, the surgical site, and the type of treatment.
